Two days after FDA advisory panel’s meeting to discuss whether oral phenylephrine is effective for nasal congestion, complaints filed in federal court in multiple states alleging manufacturers knowingly misled public about ingredient’s efficacy. FDA’s potential response to NDAC’S finding wouldn’t come as soon.

Beauty and consumer health care weren’t among the the consumer packaged goods categories showing private label market-share growth during April-June period. Consumer health industry executives see more spending on private label in some categories but without affecting their results.

Sintbilo (tafolecimab) is the first among four late-stage domestically developed PCSK9 Inhibitors to win the nod from China’s drug regulator. Despite lack of public reimbursement coverage, the drug could potentially unseat same-class rivals from Amgen and Sanofi/Regeneron.

Both health, wellness and beauty product marketers on report increased prices helped drive revenue growth during April-June period while also factoring in lower sales volumes.